FDA Expands Use of Approved Breast Cancer Drug

FDA Expands Use of Approved Breast Cancer Drug
The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

Read more on U. S. Food and Drug Administration